Previous 10 | Next 10 |
Penny stocks, or stocks with sub-$5 share prices, are rarely worth considering as a long-term investing vehicle. Most of these equities sport depressed shares prices for a very good reason, after all. Low-priced equities, however, can on the rare occasion yield life-changing returns on capi...
AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021 PR Newswire REDWOOD CITY, Calif. , March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced...
Luokung Technology (LKCO) -11%.Magnolia Oil & Gas (MGY) -11% on pricing 17M shares in secondary offering.Stratasys (SSYS) -10% on pricing ~7M stock offering.PLx Pharma (PLXP) -9% after proposed capital raise.STRATA Skin Sciences (SSKN) -8%.NanoViricides (NNVC...
AcelRx Pharmaceuticals (ACRX) has partnered with Newport Plastic and Reconstructive Surgery Associates to analyze historical data on the use of the pain drug Dsuvia in patients undergoing same-day plastic surgery procedures.Data from 70 patients will examined for endpoints such as Dsuvia util...
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures PR Newswire REDWOOD CITY, Calif. , Feb. 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical c...
AcelRx Pharmaceuticals ([[ACRX]] -10.0%) is under pressure in reaction to an FDA warning letter concerning the promotional claims for the company’s pain medication Dsuvia.The federal agency notes that ‘promotional communications, the banner and display, make false or misleading ...
It has been over two years since DSUVIA's approval, but AcelRx is finally starting to record some sales. The launch took longer than expected and the share price was punished. The Department of Defense is expected to receive ~$30M of DSUVIA in the coming years. The DoD contracts shoul...
Gainers: Obalon Therapeutics (OBLN) +438%.Caladrius Biosciences (CLBS) +121%.Adamis Pharmaceuticals (ADMP) +72%.Steel Connect (STCN) +54%.Titan Medical (TMDI) +52%.Tiziana Life Sciences (TLSA) +50%.Iterum Therapeutics (ITRM) +40%.Dare Bioscience (DARE) +33%.17 Education & T...
Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) were trading down by 16% as of 11:40 a.m. EST on Wednesday after the company announced the pricing of a public stock offering. AcelRx plans to sell 14.5 million new shares in a transaction expected to generate gross proceeds of around ...
AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock PR Newswire REDWOOD CITY, Calif. , Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...